The Global Shortage of Research Primates and Why It May Matter for Inotiv

Non-human primates (NHPs), particularly cynomolgus macaques, remain one of the most important animal models in modern drug development. Their physiological similarity to humans makes them essential for evaluating safety, pharmacokinetics, and toxicity before new drugs enter human clinical trials.

As biologic drugs, gene therapies, and other complex biologics continue to expand in development pipelines, the availability of research primates has become an increasingly important structural factor in the preclinical contract research organization (CRO) industry.

---

Global Demand for Research Primates

Globally, biomedical research is estimated to use roughly 100,000–200,000 non-human primates each year, primarily in pharmaceutical and biotechnology research programs.

The United States is one of the largest consumers of research primates, importing tens of thousands of animals annually for biomedical research.

Most of these animals are used in IND-enabling toxicology studies, which are required before a drug can enter human clinical trials.

A typical toxicology study involving cynomolgus macaques generally requires:

approximately 24–40 animals per study

depending on study design and regulatory requirements.

Given the increasing number of biologic drug candidates entering development each year, demand for NHP toxicology studies remains structurally significant.

---

Structural Supply Constraints

While demand has remained strong, global supply has become increasingly constrained.

Historically, China was one of the largest exporters of research macaques. However, during the COVID-19 pandemic China restricted exports of research primates, significantly disrupting the global supply chain.

At the same time, demand increased due to vaccine research, antiviral development, and the continued expansion of biologics pipelines.

The challenge is compounded by biology. Cynomolgus macaques require approximately four to five years of breeding before reaching research maturity, which means supply cannot quickly expand in response to demand.

Because of this, several research groups and policy organizations have described the global supply of research primates as approaching a structural bottleneck for biomedical research.

---

Price Signals in the NHP Market

Supply shortages have also been reflected in pricing.

Before the pandemic, cynomolgus macaques typically cost approximately:

$4,000–$5,000 per animal

However, during the recent shortage, prices in some markets increased to $20,000 or more per animal, reflecting the severity of supply constraints.

Although prices fluctuate depending on region and availability, the magnitude of this increase highlights how sensitive the research primate market is to supply disruptions.

---

The Role of CRO Platforms

Many pharmaceutical companies outsource toxicology studies to contract research organizations (CROs).

Major CRO companies conducting primate toxicology include:

Charles River Laboratories

Inotiv

JOINN Laboratories

WuXi AppTec

Among these companies, Charles River Laboratories is widely recognized as the largest global operator of primate research infrastructure and toxicology services.

Large CRO companies typically maintain a combination of internal primate colonies and external sourcing networks to support their toxicology programs.

Because primate availability directly affects study scheduling, access to reliable NHP supply can influence CRO operational capacity.

---

Why This May Matter for Inotiv

Through the acquisition of Envigo, Inotiv operates the Research Models & Services (RMS) segment, which includes laboratory animal supply infrastructure.

While Inotiv’s primate capacity is smaller than that of the largest CRO platforms, the company still operates an integrated system that combines research animal supply with CRO services.

Many CRO companies rely heavily on external suppliers for research primates. When supply becomes constrained, these companies may face delays in scheduling toxicology studies or higher procurement costs.

By contrast, companies with internal research animal infrastructure may have greater operational flexibility in managing study timelines.

---

A Simple Illustration of Toxicology Capacity

To understand why primate availability matters, consider a simplified example.

A typical toxicology study requires approximately:

~30 non-human primates

and typically runs for 6–9 months.

If a CRO platform has access to approximately 1,000 research primates per year, it could theoretically support around:

30 toxicology studies annually

depending on facility utilization and study design.

Since individual toxicology programs can generate several million dollars in CRO revenue, primate availability can directly influence the scale of preclinical research activity.

---

The Role of NAMs and Why NHP Demand May Continue to Grow

The development of New Approach Methodologies (NAMs)—including organ-on-chip systems, advanced in-vitro models, and AI-based toxicity prediction—has often been viewed as a potential replacement for animal testing.

However, several industry analyses, including reports from IQVIA and other CRO industry studies, suggest that the impact of NAMs may be more nuanced.

NAMs are increasingly used in the early stages of drug discovery, where they help eliminate weaker drug candidates before they reach expensive animal studies.

Paradoxically, this process can increase the probability that the remaining candidates advance into later-stage regulatory toxicology studies, where non-human primates are still frequently required.

In other words, NAMs may reduce the number of early experiments, but the programs that survive early screening tend to be higher-quality candidates that are more likely to proceed to IND-enabling toxicology studies.

Because these later-stage studies often require primate models—particularly for complex biologics—the adoption of NAMs does not necessarily eliminate NHP demand and may even contribute to sustained demand for primate toxicology programs.

---

Conclusion

The current shortage of research primates reflects a structural imbalance between the growing demand for complex biologic drug development and the limited global capacity to breed research animals.

Because primates require several years to breed and mature, supply cannot easily expand in response to short-term increases in demand.

In this environment, access to reliable primate supply becomes more than a logistical issue—it can influence the operational capacity of preclinical CRO platforms.

For companies that operate both animal supply infrastructure and CRO research services, such as Inotiv, the global shortage of research primates may therefore represent not only an industry challenge but also a potential strategic advantage.

As biologics pipelines continue to expand and drug development becomes more complex, the evolving dynamics of the global NHP supply chain may remain an important factor for investors following the preclinical CRO sector.